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Abstract  
The short-term effects of alcohol on gene expression in brain tissue cannot directly be studied in 
humans. Because neuroimmune signaling is altered by alcohol, immune cells are a logical, 
accessible choice to study and might provide biomarkers. RNAseq was used to study the effects 
of 48 h exposure to ethanol on lymphoblastoid cell lines (LCLs) from 20 alcoholics and 20 
controls. 
Ethanol exposure resulted in differential expression of 4,456 of the 12,503 genes detectably 
expressed in the LCLs (FDR ≤ 0.05); 52% of these showed increased expression. Cells from 
alcoholics and controls responded similarly. The genes whose expression changed fell into 
many pathways: NFκB, neuroinflammation, IL6, IL2, IL8, and dendritic cell maturation pathways 
were activated, consistent with increased signaling by NFκB, TNF, IL1, IL4, IL18, TLR4, and 
LPS. Signaling by Interferons A and B decreased, as did EIF2 signaling, phospholipase C 
signaling and Glycolysis.  
Baseline gene expression patterns were similar in LCLs from alcoholics and controls. At relaxed 
stringency (p<0.05), 465 genes differed, 230 of which were also affected by ethanol. There was 
a suggestion of compensation because baseline differences (no ethanol) were in the opposite 
direction of differences due to ethanol exposure in 78% of these genes. Pathways with IL8, 
phospholipase C, and α-adrenergic signaling were significant. The pattern of expression was 
consistent with increased signaling by several cytokines including interferons, TLR2 and TLR3 
in alcoholics. Expression of genes in the cholesterol biosynthesis pathway, including the rate-
limiting enzyme HMGCR, was lower in alcoholics.  
LCLs show many effects of ethanol exposure, some of which might provide biomarkers for 
alcohol use disorders. Identifying genes and pathways altered by ethanol can aid in interpreting 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
3 
 
which genes within loci identified by GWAS might play functional roles.  
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Abbreviations 
AD: Alcohol dependent by DSM-IV criteria 
LD: Linkage disequilibrium 
eQTL / QTL: (expression) quantitative trait locus 
LCLs: Lymphoblastoid cell lines 
FDR: false discovery rate 
IPA: Ingenuity pathway analysis  
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Introduction 
Alcohol dependence (AD) is a chronic relapsing brain disorder with both environmental and 
genetic contributions to risk. It is estimated that 40-60% of the difference in risk among 
individuals is due to genetic variations (Edenberg & Foroud, 2013, 2014; Rietschel & Treutlein, 
2013). However, few individual genes have been robustly associated with risk for AD. The 
largest meta-analysis to date of alcohol dependence in those of European and African Ancestry 
found only one gene associated with the disorder at genome-wide significance, ADH1B (Walters 
et al., 2018). Another metabolic gene, ALDH2, is associated with alcohol dependence in Asians 
(Edenberg and McClintick, 2018). Many of the variants for alcohol-related traits identified by 
GWAS are not in coding regions, and might be eQTLs or be in linkage disequilibrium (LD) with 
them (Gamazon et al., 2018). Transcriptome analyses may help prioritize genes within GWAS 
loci, identify the eQTLs and pathways affected by ethanol, and help understand mechanisms by 
which they act.  
Alcohol dependent individuals are chronically exposed to large quantities of ethanol. This leads 
to multiple organ damage, including the liver (Osna, Donohue, & Kharbanda, 2017), brain (Zahr 
& Pfefferbaum, 2017) and immune system (Szabo & Saha, 2015). Gene expression studies of 
post mortem human brain tissue can shed light on how the brain is damaged by and adapts to 
chronic ethanol exposure (Farris, Arasappan, Hunicke-Smith, Harris, & Mayfield, 2015; 
Flatscher-Bader et al., 2006; Hermann et al., 2017; Mayfield, Ferguson, & Harris, 2013; 
McClintick et al., 2013). Changes to the brain include direct effects of ethanol and also insults 
caused by circulating cytokines that can cross the blood-brain barrier (Crews & Vetreno, 2016). 
These studies identified effects on NFκB, TLRs, IL1β and TNFα and thereby point toward 
neuroimmune signaling as an important effect of chronic ethanol exposure and potential 
contributor to AD (Crews & Vetreno, 2016; Mayfield et al., 2013; Pascual, Pla, Miñarro, & 
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Guerri, 2014). Ethanol has been shown to potentiate and prolong the effects of proinflammatory 
cytokines and microglial activation (Qin et al., 2008). This suggests that immune cells may 
provide an accessible window into how ethanol affects gene expression. Postmortem brains 
show the effects of both potentially pre-existing differences between alcoholics and controls and 
effects of long-term exposure to high levels of alcohol. There are many unrelated variables, 
however, including cause of death, recency of exposure to ethanol, and post-mortem interval. 
Lymphoblastoid cell lines (LCLs) can be studied under controlled conditions, and have been 
used for functional studies that cannot be done with post-mortem brain tissue, such as 
identifying lithium induced gene expression changes in bipolar patients and controls (Fries et al., 
2017). Recent studies have shown strong correlations between blood and brain for cis 
expression QTLs (eQTLs) and methylation QTLs (Qi et al., 2018).  
Transcriptome-wide analysis of expression in LCLs from AD and controls may aid the 
interpretation of variants identified by genetic association studies. Treatment of LCLs with 
ethanol can reveal direct, relatively short-term effects on cellular function. In a previous 
microarray study, we examined the effects of 24 h exposure to 75 mM ethanol, which was not 
toxic to the cells, in LCLs from 21 individuals who met DSM-IV criteria for alcohol dependence 
and 21 controls (McClintick et al., 2014). The individuals from whom LCLs were created were 
carefully diagnosed as part of the Collaborative Study on the Genetics of Alcoholism (COGA) 
(Begleiter et al., 1995). Nearly half of all the expressed genes were affected by ethanol, but 
most changes were very small; fewer than 20% had absolute fold changes >1.2. Pathways 
affected included increased pro-inflammatory pathways including IL6, dendritic cell maturation, 
TNF and NFκB, and a decrease in the anti-inflammatory IL10 pathway. Analysis indicated that 
NFκB, IL6, TNF and other cytokines were likely active, along with TLRs and interferons 
(McClintick et al., 2014). There was limited power to detect differences between untreated AD 
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and controls, but decreased IGF1 signaling and increases in protein ubiquitination and hypoxia 
signaling were identified. 
Here, we have analyzed cells from the same individuals exposed to the same concentration of 
ethanol (75 mM) but for 48 h, to see if changes detected at 24 h are stable over a longer 
exposure. We also examined the untreated cells for differences in expression between AD and 
controls using data from both the 48 h and 24 h exposures. Differences between unexposed 
cells from AD and control individuals could provide insight into the genetics of AD. 
 
Methods 
Cell culture and ethanol treatment 
Lymphoblastoid cell lines (LCLs) were created by transformation with Epstein-Barr virus of 
peripheral blood mononuclear cells isolated from subjects recruited as part of the Collaborative 
Study on the Genetics of Alcoholism (Begleiter et al., 1995) and interviewed with the SSAGA 
instrument (Bucholz, et al., 1994). LCLs were from 42 individuals, 21 alcohol dependent (AD) 
and 21 controls. AD was defined as meeting DSM-IV criteria for alcohol dependence (American 
Psychiatric Association, 1994). Controls were defined as having consumed at least one drink of 
alcohol but not meeting any of four definitions of alcohol dependence: DSM-IV (American 
Psychiatric Association 1994), DSM-IIIR (American Psychiatric Association, 1987), ICD-10 
(World Health Organization, 1993), or Feighner definite alcoholism (Feighner et al., 1972); none 
were dependent on any illicit drug. These individuals were previously studied using a 24 h 
exposure to ethanol (McClintick et al., 2014).  
2 x 106 LCLs from each of 21 AD and 21 control individuals were seeded in 10 ml of RPMI1640 
medium supplemented with 15% FBS, 2 mM glutamine. Cells were cultured in the absence or 
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presence of 75 mM ethanol for 48 h, at which time cells were harvested and lysed with buffer 
RLT plus, and RNA extractions were conducted using the QIAsymphony RNA extraction 
protocol. 
RNA sequencing 
Samples were prepared in five balanced batches (4 with 8 pairs, 1 with 10 pairs) with the 
untreated and treated samples from each subject in the same batch. Samples were processed 
by polyA capture using Dynabeads mRNA DIRECT Micro Kit (Life Technologies, Carlsbad, CA) 
starting with 1.5 µg of total RNA. PolyA RNA was processed using Life Technologies SOLiDTM 
Total RNAseq kit (Life Technologies, Carlsbad, CA). Sequencing beads were produced 
separately for each batch using the SOLiDTM EZBeadTM System (Life Technologies, Carlsbad, 
CA). Each batch was sequenced separately on a SOLiD 5500xl DNA sequencer (ThermoFisher/ 
Life Technologies, Carlsbad, CA).  
Sequencing reads (75 bases, single reads) were mapped to the human hg19 reference genome 
using an in-house mapping pipeline (Breese & Liu, 2013) that utilizes bfast-0.7.0a (Homer, 
Merriman, & Nelson, 2009). In brief, reads were truncated where the average quality fell below 10 
within a window size of 5, and then reads of <35 bases were discarded. Reads mapped to 
rRNA/tRNAs were discarded. The remaining reads were mapped to reference genome hg19 
and to a splice-junction library created in-house. The genomic and splice-junction library maps 
were then merged. Reads mapped to multiple positions in the genome were excluded from 
further analysis. The gene-based expression levels were calculated using bamutils from 
NGSUtils, based on the RefSeq gene annotation of hg19. The average number of reads per 
sample was 28 million. Data deposited in GEO, GEO series <awaiting accession number>.  
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Differential expression analysis  
Reads aligned to known genes were analyzed by edgeR (Robinson, McCarthy, & Smyth, 2010). 
Counts for each sample were normalized to counts per million reads. To avoid analyzing genes 
that were not expressed or expressed at near background levels, only genes that had more than 
2 counts per million reads in at least 20 samples were retained for analysis. Data were 
examined by Multidimensional Scaling in the edgeR package (Robinson et al., 2010) and 
principal components analysis in Partek Genomics Suite (version 6.6, Partek, Inc. St. Louis, Mo) 
to detect outliers. One outlier (female, alcoholic, untreated) was found (see Supplemental Figure 
1), so we removed it and its treated pair from further processing. In addition, we discovered that 
the demographic info for one of the control samples (male) did not match the phenotype listed 
for the sample, so it was also removed from analysis, leaving 20 controls and 20 AD. Dispersion 
estimates (common, trend and tag dispersion) were calculated and used in the analysis by 
general linear methods in edgeR to identify differentially expressed genes.  
Ethanol treatment was analyzed as paired samples (treated and untreated samples from the 
same individual), which eliminated the need to use gender, phenotype and batch as factors. 
False discovery rates (FDR) were calculated using the Benjamini & Hochberg (Benjamini & 
Hochberg, 1995) method within edgeR. EdgeR paired analysis does not do a paired interaction 
of group (AD vs. control) x exposure, therefore we calculated the CPM treated – CPM untreated 
for each individual for each gene and used a t-test to see if the mean difference for each gene 
was equal between alcoholics and controls. This same method was used to test for gender 
differences in response to alcohol.  
Data on untreated cells from a previous microarray experiment that used the Affymetrix 
HGU133plus2 GeneChip™ analyzed with microarray suite 5.0 software (Affymetrix, San Clara, 
CA) were available as log2(MAS5 expression) (McClintick et al., 2014), GEO (series accession # 
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GSE52553). These data were matched by gene symbol to the log2(counts per million reads) 
from the present RNAseq experiment and imported into Partek Genomics Suite version 6.6 
(Partek, Inc. St. Louis, Mo). Both experiments had similar ranges of values (Supplemental 
Figure 2), so the most appropriate approach was to combine the log2 RMA (microarray) and log2 
CPM (sequencing) values, with a term in the ANOVA for experiment type (study) but with no 
additional normalization. The ANOVA used phenotype (AD, control), study (array, RNAseq) and 
gender as factors plus the interaction term (phenotype x study). Genes with an absolute fold 
change <1.2 were removed and genes with p< 0.05 for the interaction were removed. FDR was 
calculated within Partek using the Storey and Tibshirani method (Storey & Tibshirani, 2003).  
Pathway and upstream activator analyses 
Fold change, p-value and FDR for treatment were imported into Ingenuity Pathway Analysis 
Fall, September 2018 release (IPA; QIAGEN Inc.). For comparisons of alcohol treated vs. 
untreated cells, pathway and upstream regulator analyses were carried out on genes with FDR< 
0.05 and absolute fold ≥ 1.2, a total of 2318 genes, to keep the number within the 3000 limit 
suggested by the software vendor. For untreated cells from AD vs. control subjects, 465 genes 
with p < 0.05 and absolute fold ≥ 1.2 were compared; although the low stringency means that 
false positives will be included in the analysis, random noise should not greatly affect the results 
since pathways are tested for significance above random sets of genes. Upstream analysis 
identifies possible upstream regulators that could produce parts of the pattern of results seen in 
the data. Upstream regulators with absolute z-score ≥ 1.9 were considered to be likely causes 
of the pattern of gene expression changes. 
Comparison to gene expression data from rats and humans 
To determine if expression changes in LCLs treated with ethanol mirror changes in the brain 
and to identify genes with multiple lines of evidence for a relationship to alcohol use disorders, 
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we assembled two sets of data from microarray experiments on rat models of alcoholism. The 
first dataset was a composite of expression changes in many brain regions (amygdala and 
central core of the amygdala, nucleus accumbens and nucleus accumbens shell, dorsal raphe 
nucleus, periaqueductal grey, ventral tegmental area, ventral hippocampus, and medial pre-
frontal cortex) of P (alcohol-preferring) rats who had been voluntarily drinking ethanol in various 
paradigms from 4 to 10 weeks (Bell et al., 2009; McBride et al., 2014; McBride, Kimpel, 
McClintick, Ding, Hauser, et al., 2013; McBride et al., 2010; McClintick et al., 2015, 2016, 2018; 
Rodd et al., 2008). The second dataset compiled differences in gene expression in alcohol-
naïve animals from pairs of rat lines selected for differences in their voluntary consumption of 
ethanol (in all cases high drinking lines are listed first): five brain regions from alcohol-naïve 
inbred P and NP rat hippocampus, amygdala, frontal cortex, striatum and nucleus accumbens 
(Edenberg et al., 2005; Kimpel et al., 2007), and three regions from 5 pairs of selected lines 
(P/NP, Had1/Lad1, Had2/Lad2, sP/sNP, AA/ANA, the ventral tegmental area (McBride et al., 
2012), central core of the amygdala, and nucleus accumbens shell (McBride, Kimpel, 
McClintick, Ding, Hyytia, et al., 2013).  
In addition to the rat data, we assembled a list of differentially expressed genes from several 
studies. Gene expression data from human brain regions was obtained from the GTEx portal 
(version V7; Lonsdale et al., 2013) as median number of transcripts per million (TPM; normalized to 
gene length). Single tissue eQTL (expression quantitative trait loci) data from GTEx was used to 
identify eQTLs in EBV-transformed-lymphocytes (LCLs). Gene expression data from post-
mortem human brain tissues of AD vs. controls were obtained from both microarray and RNAseq 
(Farris, Harris, & Ponomarev, 2015; Flatscher-Bader, Harrison, Matsumoto, & Wilce, 2010; 
Flatscher-Bader et al., 2005; Iwamoto et al., 2004; Kryger & Wilce, 2010; Lewohl et al., 2000; 
Liu et al., 2004; Liu et al., 2006; Liu, Lewohl, Harris, Dodd, & Mayfield, 2007; Mayfield et al., 
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2002; McClintick et al., 2013; Ponomarev, Wang, Zhang, Harris, & Mayfield, 2012) and matched 
by gene symbol to our gene expression results.  
Comparison to GWAS results 
We assembled genetic evidence from the NHGRI-EBI GWAS Catalog (April 2018). We selected 
entries with phenotypes related to alcohol dependence and consumption and p≤ 9x10-6. These were 
matched by gene symbol to the gene expression results described above.  
 
Results and Discussion 
We examined gene expression in LCLs from alcohol dependent and control individuals to detect 
both pre-existing differences and the effects of ethanol. Because much data from brain 
transcriptome studies suggests that ethanol is associated with changes in neuroimmune genes 
and pathways (Crews & Vetreno, 2016; Mayfield et al., 2013; McClintick et al., 2013), and 
because many of the genes expressed in brain are also expressed in LCLs, LCLs are 
reasonable candidates to study both preexisting differences and effects of ethanol under 
controlled conditions. Their accessibility is a major advantage for biomarker and functional 
studies. Demographic information on the subjects whose LCLs were analyzed is in Table 1. The 
average age of onset for DSMIV AD was 16.8, and they each met 6 or 7 of the DSM-IV criteria. 
Four of the controls met one criterion, the rest none. 
Effects of ethanol treatment 
LCLs from alcohol dependent individuals (AD) and controls were exposed to ethanol (or not) for 
48 h and the differences in expression were analyzed by RNA sequencing. Cells from these 
same individuals had previously been used in a 24h exposure to ethanol (McClintick et 
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al.,2014). We have previously shown that exposure to 75 mM ethanol was not toxic to LCLs, 
and that the doubling time in the presence of ethanol was very close to that in its absence (27.7 
h vs. 27.4 h; McClintick et al., 2014). 12,503 genes were detectably expressed in the LCLs. 
Ethanol exposure resulted in differential expression of 4456 genes at FDR ≤ 0.05 (Table 2, 
Supplemental Table S1), 3716 (83%) of which are also expressed in human brain (median TPM 
≥ 2 for at least one brain region in the GTEx V7 data, Supplemental Table S1). Among the 4456 
genes, 2332 (52%) showed increased expression. Most of changes were small (Figure 1); 2318 
genes (52%) had absolute fold change ≥ 1.2. There were no significant differences in the effects 
of ethanol on cells from AD individuals and controls, nor were there significant differences in the 
effects of ethanol on cells from men and women.  
Many genes associated with inflammatory responses, including interleukins and chemokines, 
were affected by ethanol (Table 2). These fell into many pathways (Supplemental Table S2). 
Pathways related to inflammation and neuroimmune activation showed increased overall 
expression in the alcohol-treated cells, including neuroinflammation signaling, Th1 and Th2 
activation, NFκB, interleukin signaling, STAT3, JAKs in cytokine signaling, and T-cell receptors. 
Higher activation of neuroimmune pathways has been shown in post-mortem brain tissue from 
alcoholics (Crews, Qin, Sheedy, Vetreno, & Zou, 2013; McClintick et al., 2013) and in animal 
studies (Blednov et al., 2011; Qin et al., 2008). Chronic activation of neuroimmune pathways is 
one of the hallmarks of alcohol use disorders (Crews & Vetreno, 2016; Mayfield et al., 2013). 
Analyses of upstream regulators indicate that the observed changes in expression could be 
related to ethanol’s activation of Toll-like receptors, NFκB, and TNF. Lipopolysaccharide (LPS) 
was also listed as a putative regulator, although the LCLs were not exposed to LPS, indicating 
that the changes were similar to those seen when exposed to LPS, i.e. immune stimulation. In 
contrast to the 24 h study (McClintick et al., 2014), which showed increased interferon signaling, 
cells exposed for 48 h show reduced interferon signaling (Supplementary Tables S2 and S3).  
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Among genes affected by ethanol treatment, STXBP1 (syntaxin binding protein 1), PEA15 
(phosphoprotein enriched in astrocytes 15), NPDC1 (neural proliferation, differentiation and 
control 1), NRXN3 (neurexin 3), SYT11 (synaptotagmin 11), CBLN3 (cerebellin 3 precursor), 
SYNGR1 (synaptogyrin 1), synaptophilin, and SYNPO (synaptopodin) are highly expressed in 
brain (Table 2). Several of these produce proteins that are known to reside in the post-synaptic 
density (Bayes et al., 2011). Ethanol caused a large decrease in the expression of GRM8 
(glutamate metabotropic receptor 8), SSTR3 (somatostatin receptor 3) and CHRNB1 
(cholinergic receptor nicotinic beta 1 subunit). The SSTR2 (somatostatin receptor 2) and 
CHRNA5 (cholinergic receptor nicotinic alpha 5 subunit) are increased.  
We examined other datasets to look for converging evidence supporting a potential role for the 
genes affected by ethanol in either predisposition to or effects of ethanol. Studies of post 
mortem brains from AD vs. control individuals have identified 928 of these 4456 genes as 
differentially expressed in at least one brain region (Supplemental Table S1). Forty-eight genes 
show some evidence of association with alcohol dependence or consumption in the NHGRI 
catalog (at p ≤ 9x10-6; Table 4 and Supplemental table S1). Genes differentially expressed in 
the brains of P rats consuming large amounts of ethanol over the course of 4 to 10 weeks (Bell 
et al., 2009; McBride et al., 2014; McBride, Kimpel, McClintick, Ding, Hauser, et al., 2013; 
McBride et al., 2010; McClintick et al., 2015, 2016, 2018) matched 1214 of the genes affected 
by ethanol exposure in the LCLs (Supplemental Table S1). Some genes show evidence from 
several of these analyses. For example, TSPAN5 (tetraspanin 5) is decreased in the 
hippocampus (McClintick et al., 2013) and frontal cortex (Liu et al., 2007) of alcoholics, 
increased in the dorsal raphe nucleus (McClintick et al., 2015) and central core of the amygdala 
(McBride et al., 2010) of P rats in binge-like models of drinking, and associated with alcohol 
consumption (Clarke, et al., 2017). AUTS2 (activator of transcription and developmental 
regulator) has been associated with alcohol drinking (Schumann et al., 2011) and was 
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decreased in post-mortem frontal cortex of alcoholics (Liu et al., 2007). CHL1 (cell adhesion 
molecule L1 like) was associated with response to trauma and total AUDIT score (Almli et al., 
2017) and decreased in post-mortem frontal cortex (Liu et al., 2007).  
Baseline differences between LCLs from alcohol-dependent and control subjects 
Baseline expression differences between LCLs derived from AD subjects vs. controls could 
result either from pre-existing genetic differences that affect risk for AD or from effects of the 
long-term alcohol exposure of the AD subjects from whom they came. Transformation and 
growth of the LCL would be expected to reduce differences due to the previous drinking history. 
Differences were, in fact, small and our data both here and in the previous experiment on LCLs 
from the same individuals (McClintick et al., 2014) were underpowered to identify them. Even 
combining the data on unexposed cells identified only 9 genes with an FDR < 0.20 (Table 3, 
Supplemental table S4). To see if there were suggestions of effects, we relaxed the criteria for 
this combined analysis to p< 0.05; 465 genes showed differences ≥1.2-fold. TMOD2, CLIC2, 
NPNT, EIF1AY, FYB, TANC1 and KCNA1 were expressed at much lower levels in cells from 
AD, and WFDC2, TIE1, ASB2, MUC13, and FOXA3 were expressed at much higher levels 
(Table 3).  
Among the genes that differed at baseline, 230 were affected by ethanol, 180 of which differed 
in the opposite direction (Table 3, Supplemental Table S4). This strong bias is not likely due to 
chance (180/230, p=1.0x10-17), and suggests that the heavy drinking history in the AD subjects 
may have led to changes that compensate for the effects of ethanol.  
Some genes that differ between AD and controls have prominent roles in brain function and 
were identified as either genome-wide or nominally significant by GWAS, making them 
promising targets for follow-up studies. SASH1 (SAM and SH3 domain containing 1) is a 
scaffold protein involved in the TLR4 signaling pathway that has been linked to the inflammation 
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seen in chronic drinking (Crews et al., 2015; Kelley & Dantzer, 2011) and associated with 
unipolar depression and alcohol dependence (Zhou et al., 2017). SIX3, a homeobox gene and 
transcriptional regulator important during forebrain development, is associated with alcohol and 
nicotine codependence (Zuo et al., 2012). SLC35F3 (solute carrier family 35 member F3) is a 
probable thiamine transporter expressed at highest levels in brain (GTEx); an intronic variant, 
rs17514104, is suggestively associated with dependence on at least one substance (alcohol, 
cannabis, opioid or cocaine) in the COGA sample (Wetherill et al., 2015). FYB, FYN binding 
protein, is associated with the innate immune system and T-cell receptor signaling; 
rs113497429, in an intron of FYB, is suggestively associated with alcohol use disorder symptom 
count (Gelernter et al., 2015). Two intronic SNPs in TNFRSF10A, rs73222599 and rs73222600, 
were also suggestive with symptom count in African Americans (Gelernter et al., 2015) 
(Gelernter et al., 2014); TNFRSF10A (TNF receptor superfamily member 10a) is a receptor for 
the ligand Trail (TNF-related apoptosis-inducing ligand) that can mediate neuronal apoptosis 
(Ryan et al., 2004). FOXA3 (forkhead box A3), more highly expressed in AD and was 
decreased by ethanol treatment, plays a role in neuronal death after seizure-induced neuronal 
injury (Kim et al., 2014). 
Two genes with large differences between untreated cells from AD vs. control subjects are 
involved in formation and maintenance of synapses: TMOD2 (tropomodulin) and TANC1 
(tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1). TMOD2 is a negative 
regulator of neurites and is expressed mostly in neurons (Fath, Fischer, Dehmelt, Halpain, & 
Fowler, 2011). TANC1 is in the post synaptic density and may be important for dendritic spine 
maintenance (Han et al., 2010).  
The 465 nominally significant genes mapped to sixty-seven pathways (Supplemental Table S5). 
Cholesterol biosynthesis was one of the most significant, with lower expression of HMGCR, 
CYP51A1 and IDI1. Chronic ethanol exposure has been shown to decrease cholesterol 
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synthesis with an associated decrease in myelination in humans (Liu et al., 2006, McClintick et 
al., 2013) and animals (Alfonso-Loeches et al., 2012; McClintick et al., 2013; Pascual et al., 
2014), leading to losses in white matter in the brain (Jacobus & Tapert, 2013). Upstream 
analysis was consistent with higher activity of TP53, TNF, LPS, TLRs, interferons and 
interleukins (Supplemental Table S6). In contrast to the effects of ethanol treatment, the 
analysis indicates Phospholipase C has higher activity in alcoholics. 
Among the 465 genes, expression differences between alcohol-naïve rats from 5 selectively 
bred pairs of high-drinking and low-drinking rats were found for 138 of the genes that differed at 
baseline, eQTLs from lymphocytes (GTEx) affected 83 of these genes, and 6 were found in the 
NHGRI catalog (Supplemental Table 4). Three GWAS genes, CASZ1 (castor zinc finger 1), 
MREG (melanoregulin) and ST3GAL1 (ST3 beta-galactoside alpha-2,3-sialyltransferase 1), 
were affected by ethanol with a direction opposite those for AD vs. controls.  
 
Conclusions 
The results of this study provide additional data on genes potentially linked either to the 
development of alcohol dependence or the effects of excessive alcohol. There are, however, 
limitations. Even though most of the genes we found differentially expressed in the LCLs 
exposed to ethanol are also expressed in brain, the changes we found might not mirror what 
happens in the brain. Long-term drinking patterns are highly variable, and not replicated in vitro; 
our goal was to determine if there is molecular evidence of either adaptation or increased 
perturbation of gene expression after 48 h of exposure, compared to 24 h. Differences at 
baseline (unexposed cells) were very small, and because we were underpowered to detect 
many we relaxed our statistical criteria to examine trends.   
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This study shows that ethanol exposure induces many changes in LCLs, including a robust 
immune response seen strongly after 24 h exposure, but decreased in intensity, possibly due to 
a reversal of interferon signaling, after 48 h exposure. Some expression differences between 
the LCL from AD and controls are likely genetic, since those groups differ in genetic risk for AD. 
Accessible tissues like LCLs can be useful in interpreting GWAS results, and giving additional 
support to prioritize genes that don’t quite reach genome wide significance for follow-up studies.  
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files:  
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eQTL data: GTEx_Analysis_v7_eQTL.tar.gz 
 
NHGRI-EBI GWAS Catalog (April 2018);  
https://www.ebi.ac.uk/gwas/docs/file-downloads 
file: NHGRI_gwas_catalog_v1.0.1-associations_e92_r2018-04-10 
 
Partek Genomics Suite (version 6.6, Partek, Inc. St. Louis, Mo) 
http://www.partek.com/pgs) 
 
Ingenuity Pathway Analysis (Fall, September 2018 release) 
www.qiagenbioinformatics.com/products/ingenuitypathway-analysis). 
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Tables and Figures 
Table 1. Demographics of AD and controls used in this project; mean values (standard 
deviations).  
Table 2. Genes differentially expressed after 48 hr. treatment with ethanol; this is a subset with 
absolute fold ≥ 1.6 plus any genes discussed in the text. The full set of genes is in Supplemental 
Table S1. FDR = false discovery rate.  
Table 3. Genes differentially expressed at baseline between alcohol dependent and control 
individuals. This is a subset with absolute fold ≥ 1.5; the full list is in Supplemental Table S4.  
*fold change for ethanol treatment shown only when FDR< 0.05.  
Table 4. Differentially expressed genes that matched genes for alcohol dependence or 
consumption that were significant or nominally significant (p<9x10-6) in the NHGRI GWAS 
catalog. TPM = highest value of transcripts per million transcripts in any brain region in the 
GTEx database. 
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Figure 1. Distribution of Absolute fold changes for treated vs. untreated LCLs.  
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Supplemental Data 
Supplemental Figure 1. MDS plot from edgeR showing outlier 1U. Note that most other 
Treated (T) and Untreated (U) pairs (same number) group together. 1U does not group with 1T 
and is separated on the first axis from the rest of the samples. We removed 1U and 1T from 
further processing. 
Supplemental Figure 2. Box plots of log base 2 transformed CPM for RNAseq and RMA for 
microarray data. 
 
Supplemental Table S1. Full list of differentially expressed genes after LCLs were treated with 
ethanol for 48h, FDR < 0.05. 
Supplemental Table S2. IPA Pathways for genes affected by ethanol treatment of LCLs.  
Supplemental Table S3. IPA Upstream analysis of genes affected by ethanol treatment of 
LCLs.  
Supplemental Table S4. Full list of gene expression differences between alcohol dependent 
and control individuals.  
Supplemental Table S5. IPA Pathways for genes that differed between alcohol dependent vs. 
controls. 
Supplemental Table S6. IPA Upstream analysis of genes that differed between alcohol 
dependent vs. controls. 
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Table 1. Demographics of AD and controls used in this project; mean values (standard 
deviations). 
AD control 
Male 12 11 
Female 8 9 
DSM4 criterion count 6.8 (0.6) 0.2 (0.4) 
Age DSM4 onset 16.7 (1.0) NA 
max drinks 35.0 (15.4) 8.2 (3.3) 
age 55.4 (7.5) 64.0 (16.7) 
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Table 2. Genes differentially expressed after 48 hr. treatment with ethanol. S; this is a subset 
with absolute fold ≥ 1.6 plus any genes discussed in the text. The full set of genes is in 
Supplemental Table S1. FDR = false discovery rate. 
gene symbol gene name 
treated/ 
untreated 
fold 
treated/ 
untreated 
FDR 
ABCA1 ATP binding cassette subfamily A 
member 1 -1.7 1.19E-03 
ABCB1 ATP binding cassette subfamily B 
member 1 2.2 1.44E-30 
ACY3 aminoacylase 3 -1.7 1.37E-38 
ADCY1 adenylate cyclase 1 1.6 3.43E-15 
AFF3 AF4/FMR2 family member 3 1.8 4.70E-15 
ANGPTL6 angiopoietin like 6 -1.6 6.17E-16 
ANKRD30BL ankyrin repeat domain 30B like -1.8 8.23E-04 
ANXA3 annexin A3 1.7 6.79E-09 
APOBEC3H apolipoprotein B mRNA editing 
enzyme catalytic subunit 3H -1.8 1.65E-28 
AQP9 aquaporin 9 1.6 1.13E-15 
BAG3 BCL2 associated athanogene 3 1.7 9.60E-12 
BCO1 beta-carotene oxygenase 1 -1.6 4.58E-15 
BEX2 brain expressed X-linked 2 1.7 4.76E-17 
BMP4 bone morphogenetic protein 4 1.6 1.26E-11 
C14orf105 
 
-1.6 1.70E-39 
C1orf228 
 
-1.8 2.94E-22 
CABP1 calcium binding protein 1 -1.6 1.40E-14 
CADM1 cell adhesion molecule 1 1.6 7.87E-13 
CAV2 caveolin 2 1.8 1.53E-04 
CCL22 C-C motif chemokine ligand 22 1.6 2.59E-24 
CCR8 C-C motif chemokine receptor 8 1.7 7.21E-22 
CD68 CD68 molecule -1.7 6.70E-29 
CDHR1 cadherin related family member 1 1.6 2.04E-36 
CEP170B centrosomal protein 170B 1.6 9.25E-06 
CLLU1OS chronic lymphocytic leukemia up-
regulated 1 opposite strand -1.7 2.40E-16 
CPEB1 cytoplasmic polyadenylation 
element binding protein 1 1.8 2.65E-18 
CREB3L1 cAMP responsive element binding protein 3 like 1 1.6 2.48E-12 
CXCL10 C-X-C motif chemokine ligand 10 1.8 7.28E-22 
CYP1A1 cytochrome P450 family 1 
subfamily A member 1 -1.7 8.97E-26 
DBNDD1 dysbindin domain containing 1 -1.8 5.51E-25 
DDX60L DExD/H-box 60 like -1.6 2.59E-25 
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DNAH14 dynein axonemal heavy chain 14 1.6 1.76E-05 
DZIP1 DAZ interacting zinc finger protein 1 1.6 3.99E-32 
EIF4E3 eukaryotic translation initiation factor 4E family member 3 1.7 1.99E-08 
ELK2AP ELK2A, member of ETS 
oncogene family, pseudogene -1.6 1.69E-05 
EPHB2 EPH receptor B2 1.7 2.71E-12 
ESPNL espin like -1.8 7.91E-25 
F5 coagulation factor V 1.8 5.28E-21 
FABP3 fatty acid binding protein 3 -1.7 3.92E-28 
FAM171A1 family with sequence similarity 171 member A1 1.6 9.17E-11 
FCHO2 FCH domain only 2 1.6 6.46E-07 
FFAR2 free fatty acid receptor 2 -2.0 2.77E-27 
FLRT3 fibronectin leucine rich transmembrane protein 3 1.6 8.03E-08 
GBP4 guanylate binding protein 4 1.6 4.35E-20 
GJB2 gap junction protein beta 2 1.9 1.21E-27 
GNAI1 G protein subunit alpha i1 1.8 4.80E-07 
GPER1 G protein-coupled estrogen 
receptor 1 -1.8 8.88E-24 
GPR153 G protein-coupled receptor 153 1.6 5.09E-15 
GRM8 glutamate metabotropic receptor 8 -1.8 1.49E-17 
HIST1H1C histone cluster 1 H1 family 
member c -1.8 2.06E-19 
HRASLS2 HRAS like suppressor 2 -1.7 2.40E-11 
IGF1 insulin like growth factor 1 -1.6 3.78E-15 
IGFBP2 insulin like growth factor binding protein 2 -1.8 4.83E-07 
IGFBP4 insulin like growth factor binding protein 4 1.6 1.93E-14 
IL18R1 interleukin 18 receptor 1 1.8 2.68E-68 
IL1R2 interleukin 1 receptor type 2 1.6 1.41E-10 
JPH4 junctophilin 4 1.7 1.64E-12 
KCNMA1 potassium calcium-activated 
channel subfamily M alpha 1 1.6 7.36E-11 
KCNMB2 
potassium calcium-activated 
channel subfamily M regulatory 
beta subunit 2 
-1.8 2.65E-20 
KHDRBS3 
KH RNA binding domain 
containing, signal transduction 
associated 3 
1.7 1.30E-09 
KIAA0408 KIAA0408 1.7 1.13E-14 
KIF7 kinesin family member 7 1.7 2.42E-09 
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KITLG KIT ligand 1.8 2.38E-05 
LARP6 La ribonucleoprotein domain family member 6 1.7 1.69E-08 
LHFP 
 
1.6 9.61E-22 
LOC101927412 
 
-1.8 6.80E-13 
LOC63930 
 
-1.6 5.69E-10 
LRRC25 leucine rich repeat containing 25 -1.8 6.08E-19 
MAN1C1 mannosidase alpha class 1C 
member 1 1.9 1.63E-21 
MEOX1 mesenchyme homeobox 1 1.8 2.27E-47 
MIR6787 microRNA 6787 -1.6 4.45E-03 
MMRN1 multimerin 1 1.6 1.97E-08 
MSRB3 methionine sulfoxide reductase B3 1.8 1.03E-06 
MYBPC2 myosin binding protein C, fast type -1.9 1.37E-14 
MYO7B myosin VIIB -1.6 2.96E-09 
NBL1 
 
1.7 1.66E-10 
NCS1 neuronal calcium sensor 1 1.8 1.50E-08 
NEB nebulin -1.8 2.90E-03 
NOTCH2 notch 2 1.7 4.95E-37 
NPDC1 neural proliferation, differentiation 
and control 1 1.9 4.55E-11 
NPL N-acetylneuraminate pyruvate lyase 1.6 1.21E-34 
NRXN3 neurexin 3 1.6 9.30E-07 
PDZD2 PDZ domain containing 2 -1.9 2.21E-11 
PHKA1 phosphorylase kinase regulatory 
subunit alpha 1 1.8 4.55E-09 
PLD4 phospholipase D family member 4 -2.2 1.89E-31 
PLEKHA5 pleckstrin homology domain 
containing A5 1.7 6.34E-06 
PODXL podocalyxin like 1.7 1.85E-18 
PPFIA4 PTPRF interacting protein alpha 4 -1.7 4.41E-16 
PSD3 pleckstrin and Sec7 domain 
containing 3 -1.6 1.00E-04 
PTPRO protein tyrosine phosphatase, 
receptor type O -1.6 4.60E-19 
PVR poliovirus receptor 1.6 9.10E-24 
PXDC1 PX domain containing 1 1.7 9.30E-18 
RAB15 RAB15, member RAS oncogene family 1.7 6.40E-28 
RAB32 RAB32, member RAS oncogene family 1.8 5.74E-18 
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RNF130 ring finger protein 130 1.7 6.79E-08 
RPS6KA6 ribosomal protein S6 kinase A6 1.6 1.71E-09 
RSAD2 radical S-adenosyl methionine domain containing 2 -1.7 4.51E-41 
SCD5 stearoyl-CoA desaturase 5 1.6 6.27E-22 
SERPINB6 serpin family B member 6 1.7 1.10E-08 
SETD7 SET domain containing lysine 
methyltransferase 7 2.3 2.39E-32 
SFRP1 secreted frizzled related protein 1 1.7 1.88E-07 
SLC16A14 solute carrier family 16 member 14 2.1 2.27E-47 
SLC16A9 solute carrier family 16 member 9 2.0 1.04E-76 
SLC47A1 solute carrier family 47 member 1 1.6 1.30E-09 
SLC9A2 solute carrier family 9 member A2 1.6 4.92E-12 
SMARCA1 
SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, subfamily 
a, member 1 
1.6 6.75E-04 
SNPH syntaphilin 1.9 4.03E-15 
SNX7 sorting nexin 7 1.6 1.10E-08 
SOAT2 sterol O-acyltransferase 2 -1.6 1.84E-11 
SOGA3 SOGA family member 3 1.6 7.35E-15 
SRGAP1 SLIT-ROBO Rho GTPase 
activating protein 1 1.6 3.17E-09 
SSTR2 somatostatin receptor 2 1.5 6.79E-27 
SSTR3 somatostatin receptor 3 -1.5 1.28E-19 
STAT4 signal transducer and activator of transcription 4 1.7 6.96E-29 
STK39 serine/threonine kinase 39 1.6 9.98E-08 
STXBP1 syntaxin binding protein 1 1.9 1.01E-17 
TCL6 T cell leukemia/lymphoma 6 -1.9 1.28E-15 
TFCP2L1 transcription factor CP2 like 1 -2.6 7.06E-29 
TFPI2 tissue factor pathway inhibitor 2 1.6 1.27E-10 
TMEM136 transmembrane protein 136 1.6 6.48E-14 
TMEM217 transmembrane protein 217 1.7 2.86E-23 
TNFSF4 TNF superfamily member 4 1.8 1.74E-36 
TPBG trophoblast glycoprotein 1.6 4.83E-21 
TUFT1 tuftelin 1 1.6 1.02E-18 
VASH1 vasohibin 1 1.6 2.04E-12 
VAV3 vav guanine nucleotide exchange factor 3 1.8 3.13E-14 
VCAM1 vascular cell adhesion molecule 1 1.8 3.76E-30 
VPREB3 V-set pre-B cell surrogate light 
chain 3 -1.9 2.07E-12 
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Table 3. Genes differentially expressed at baseline between alcohol dependent and control 
individuals. This is a subset with absolute fold ≥ 1.5; the full list is in Supplemental Table S4.  
*fold change for ethanol treatment shown only when FDR< 0.05. 
gene 
symbol gene name 
AD / Ctl 
Fold 
AD / Ctl 
pvalue 
ethanol 
fold* 
ACOXL acyl-CoA oxidase-like 1.5 1.10E-02 
 ADCY1 adenylate cyclase 1 -1.7 2.74E-02 1.6 
AMICA1 Junction Adhesion Molecule Like (JAML) 1.5 2.56E-02 -1.1 
ARHGAP24 Rho GTPase activating protein 24 -1.5 2.54E-02 1.1 
ARMCX1 armadillo repeat containing, X-linked 1 -1.5 4.33E-02 1.5 
ASB2 ankyrin repeat and SOCS box 
containing 2 1.9 3.67E-04  
ATP8B1 ATPase phospholipid transporting 8B1 1.9 1.54E-03  
BCL11A B-cell CLL/lymphoma 11A -1.6 4.40E-03 -1.2 
C3orf14 chromosome 3 open reading frame 14 -1.9 2.28E-02 1.3 
CADM1 cell adhesion molecule 1 -1.9 2.84E-02 1.6 
CCDC74A coiled-coil domain containing 74A -1.7 5.41E-03 1.2 
CD200R1 CD200 receptor 1 1.6 4.56E-03 
 
CDC42BPA CDC42 binding protein kinase 
alpha 1.7 2.04E-02  
CLIC2 chloride intracellular channel 2 -2.1 3.63E-04 1.4 
CNTLN centlein -2.1 2.51E-02 1.2 
DLGAP1 DLG associated protein 1 1.5 4.76E-02 
 
DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 -1.5 4.35E-02 1.1 
EFNA5 ephrin A5 -1.6 2.10E-02 1.2 
EFR3B EFR3 homolog B -1.6 4.22E-02 
 
EIF1AY eukaryotic translation initiation factor 1A, Y-linked -1.9 1.47E-02  
F2R coagulation factor II thrombin 
receptor 1.5 2.66E-02 1.3 
FAM160A1 family with sequence similarity 160 member A1 -1.5 1.62E-02  
FAM171A1 family with sequence similarity 171 member A1 -1.5 8.95E-03 1.6 
FAM26F family with sequence similarity 26 
member F -1.6 2.49E-02 -1.2 
FCRL4 Fc receptor like 4 1.5 4.88E-02 
 FCRL5 Fc receptor like 5 1.5 7.27E-03 -1.4 
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FNIP2 folliculin interacting protein 2 1.5 2.55E-02 
 FOXA3 forkhead box A3 1.7 7.91E-03 -1.2 
FYB FYN binding protein -2.1 1.46E-03 1.3 
HIC1 HIC ZBTB transcriptional 
repressor 1 1.5 2.54E-02 -1.3 
HMX2 H6 family homeobox 2 -2.0 2.75E-02 1.2 
HNF4G hepatocyte nuclear factor 4 gamma 1.7 2.41E-02  
HNMT histamine N-methyltransferase -1.8 3.28E-02 
 
HNRNPLL heterogeneous nuclear 
ribonucleoprotein L like 1.6 6.34E-04 1.3 
IL23R interleukin 23 receptor 1.7 3.70E-02 
 
INA internexin neuronal intermediate filament protein alpha -1.5 2.30E-02  
KCNA1 potassium voltage-gated channel 
subfamily A member 1 -1.8 1.64E-03 1.2 
KCNMB2 
potassium calcium-activated 
channel subfamily M regulatory 
beta subunit 2 
1.5 3.22E-02 -1.8 
KIAA0226L #N/A 1.6 1.72E-02 -1.1 
KIAA1549L KIAA1549 like -1.5 4.10E-02 1.2 
LEF1 lymphoid enhancer binding factor 1 1.6 2.31E-02 1.2 
LINC01225 LINC01225 pseudogene 1.8 1.12E-02 
 LMO3 LIM domain only 3 1.6 2.75E-02 
 LRRC1 leucine rich repeat containing 1 1.5 1.33E-02 1.1 
MAATS1 MYCBP associated and testis 
expressed 1 -1.5 5.69E-03 1.3 
MACROD2 MACRO domain containing 2 1.7 4.57E-03 -1.1 
MTTP microsomal triglyceride transfer protein 1.5 2.61E-02  
MUC13 mucin 13, cell surface associated 2.2 1.22E-02 
 
MYBPC2 myosin binding protein C, fast type 1.6 3.37E-03 -1.9 
NCKAP5 NCK associated protein 5 1.7 2.32E-02 -1.3 
NOL4 nucleolar protein 4 -1.9 3.98E-02 1.2 
NPNT nephronectin -2.5 4.08E-03 1.5 
PDZD2 PDZ domain containing 2 1.7 2.50E-02 -1.9 
PIEZO2 piezo type mechanosensitive ion 
channel component 2 -1.5 3.06E-02  
PYROXD1 pyridine nucleotide-disulphide 
oxidoreductase domain 1 1.5 1.99E-02 -1.1 
RAB3B RAB3B, member RAS oncogene family -1.5 3.15E-02  
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RBPMS2 RNA binding protein with multiple 
splicing 2 1.7 9.90E-03  
RHOU ras homolog family member U 1.6 4.40E-02 -1.2 
RIMS2 regulating synaptic membrane 
exocytosis 2 1.5 3.99E-02  
SAMD12 sterile alpha motif domain 
containing 12 1.5 1.50E-02  
SASH1 SAM and SH3 domain containing 1 1.8 4.21E-03  
SEL1L3 SEL1L family member 3 1.6 1.13E-03 -1.4 
SEMA6A semaphorin 6A 1.5 8.52E-03 
 SERPINE2 serpin family E member 2 1.5 4.43E-02 
 SFRP1 secreted frizzled related protein 1 -1.9 4.56E-02 1.7 
SHTN1 shootin 1 -1.7 2.31E-03 1.2 
SIX3 SIX homeobox 3 -1.9 1.80E-02 
 
SLC35F3 solute carrier family 35 member F3 -1.5 4.80E-02 1.5 
SNTB1 syntrophin beta 1 1.6 1.58E-03 
 STEAP1 STEAP family member 1 1.6 4.65E-02 -1.1 
SYNGR1 synaptogyrin 1 1.7 1.20E-02 -1.2 
TANC1 
tetratricopeptide repeat, ankyrin 
repeat and coiled-coil containing 
1 
-1.9 1.81E-03 1.2 
TBC1D30 TBC1 domain family member 30 -1.5 4.68E-02 1.5 
TC2N tandem C2 domains, nuclear -1.6 3.95E-03 1.2 
TIE1 
tyrosine kinase with 
immunoglobulin like and EGF like 
domains 1 
2.2 3.43E-04 
 
TMOD2 tropomodulin 2 -1.5 2.01E-05 1.3 
TNFRSF10A TNF receptor superfamily 
member 10a 1.5 3.32E-04  
WFDC2 WAP four-disulfide core domain 2 2.4 7.63E-04 -1.5 
ZNF300 zinc finger protein 300 -1.8 1.45E-02 
 ZNF880 zinc finger protein 880 1.5 2.13E-02 -1.1 
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Table 4. Differentially expressed genes that matched genes for alcohol dependence or 
consumption that were significant or nominally significant (p<9x10-6) in the NHGRI GWAS 
catalog. TPM = highest value of transcripts per million transcripts in any brain region in the 
GTEx database. 
gene symbol gene name 
treated/ 
untreated 
fold 
treated / 
untreated 
FDR 
TPM 
GTEx 
brain 
ANKRD44 ankyrin repeat domain 44 -1.1 1.99E-02 1.6 
ARL15 ADP ribosylation factor like GTPase 15 1.2 6.90E-03 12.0 
AUTS2 AUTS2, activator of transcription 
and developmental regulator 1.3 6.50E-22 14.6 
B4GALT6 beta-1,4-galactosyltransferase 6 1.3 3.51E-06 28.9 
BOD1 biorientation of chromosomes in 
cell division 1 1.2 1.23E-04 48.0 
BPTF bromodomain PHD finger transcription factor -1.1 5.35E-03 38.2 
C2orf88 chromosome 2 open reading frame 88 -1.1 1.99E-03 4.7 
CAMTA1 calmodulin binding transcription 
activator 1 -1.1 1.55E-03 57.0 
CAPN7 calpain 7 1.2 2.56E-04 28.0 
CASZ1 castor zinc finger 1 1.3 3.48E-04 0.6 
CHL1 cell adhesion molecule L1 like -1.3 2.20E-12 39.1 
CTNNA2 catenin alpha 2 -1.3 5.34E-03 63.7 
FABP3 fatty acid binding protein 3 -1.7 3.92E-28 135.4 
FAM81A family with sequence similarity 81 
member A 1.1 1.76E-04 32.5 
FAM83D family with sequence similarity 83 
member D 1.2 3.06E-06 1.9 
GALNT18 polypeptide N-
acetylgalactosaminyltransferase 18 1.1 2.43E-02 27.0 
GPD1L glycerol-3-phosphate dehydrogenase 1 like 1.1 9.67E-03 34.1 
IGSF9B immunoglobulin superfamily 
member 9B 1.3 3.17E-03 16.7 
ITPRIPL2 ITPRIP like 2 1.2 4.26E-04 2.0 
KCND2 potassium voltage-gated channel 
subfamily D member 2 1.2 3.38E-07 79.4 
LARGE 
 
1.1 6.91E-04 15.3 
LINC00158 long intergenic non-protein coding RNA 158 1.2 6.79E-03 1.4 
LOC101927697 
 
-1.2 1.12E-03 
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MICU3 mitochondrial calcium uptake family 
member 3 1.3 2.83E-02 60.0 
MREG melanoregulin 1.4 3.57E-18 34.8 
NAA30 N(alpha)-acetyltransferase 30, NatC catalytic subunit 1.2 1.37E-04 12.9 
NCALD neurocalcin delta 1.2 9.62E-11 87.8 
NEB nebulin -1.8 2.90E-03 0.7 
NR2C2 nuclear receptor subfamily 2 group C member 2 1.1 8.49E-04 9.8 
NR4A2 nuclear receptor subfamily 4 group A member 2 -1.2 4.60E-03 34.0 
OAS3 2'-5'-oligoadenylate synthetase 3 -1.3 9.26E-20 3.8 
OXTR oxytocin receptor 1.5 3.91E-30 6.6 
PLEKHG1 pleckstrin homology and RhoGEF domain containing G1 1.4 2.57E-10 6.6 
PODXL podocalyxin like 1.7 1.85E-18 29.5 
PPP1R16B protein phosphatase 1 regulatory 
subunit 16B 1.1 1.32E-03 94.9 
RB1 RB transcriptional corepressor 1 -1.2 6.84E-03 18.8 
RPS3 ribosomal protein S3 -1.2 2.41E-02 164.7 
RUNX3 runt related transcription factor 3 1.2 4.57E-13 0.9 
SERINC2 serine incorporator 2 -1.2 1.67E-03 1.8 
SMIM20 small integral membrane protein 20 -1.1 2.51E-04 25.6 
ST3GAL1 ST3 beta-galactoside alpha-2,3-
sialyltransferase 1 -1.3 2.85E-20 7.7 
STAG3 stromal antigen 3 -1.3 3.19E-14 11.2 
TANK TRAF family member associated NFKB activator 1.2 6.55E-03 11.0 
TNN tenascin N -1.5 4.15E-12 0.1 
TRIM71 tripartite motif containing 71 -1.2 9.68E-03 1.0 
TSPAN5 tetraspanin 5 1.4 2.40E-11 153.0 
WDR7 WD repeat domain 7 1.1 1.39E-03 17.6 
ZNF697 zinc finger protein 697 1.1 9.26E-05 3.0 
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Highlights  
• 48 h treatment of LCLs with ethanol activates immune signaling. 
• Immune signaling increased without exposure to LPS.  
• Interferon signaling is decreased in 48h compared to 24h treatment with ethanol. 
• At baseline, cholesterol synthesis genes are lower in alcoholics than in controls.  
• At baseline, cytokines in are more highly expressed in alcoholics than controls. 
